Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-escalation and Dose-expansion Study of KMV002 in Patients With Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer

NCT07866300 is registered in ClinicalTrials.gov with Chimivac INC as lead sponsor.

NCT NCT07866300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07866300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-escalation and Dose-expansion Study of KMV002 in Patients With Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer
Lead sponsor
Chimivac INC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
September 30, 2030
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic castration-resistant